Carregant...
The use of a new combination of avelumab + axitinib in patients with metastatic kidney cancer in the first line of treatment
Introduction. Simultaneous inhibition of programmed cell death-1 (PD-1)/PD-L1 immune checkpoint and VEGF/VEGFR signaling has a synergistic antitumor effect in preclinical models. This article presents the results of the phase III study JAVELIn Renal 101 (NCT02684006), as well as the experience...
Guardat en:
| Autors principals: | , , |
|---|---|
| Format: | Artigo |
| Idioma: | Russo |
| Publicat: |
Remedium Group LLC
2021-06-01
|
| Col·lecció: | Медицинский совет |
| Matèries: | |
| Accés en línia: | https://www.med-sovet.pro/jour/article/view/6209 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|